Hereditary Angioedema Therapeutic Market - Global Outlook and Forecast 2023-2028

Report ID: 1567107 | Published Date: Jan 2025 | No. of Page: 69 | Base Year: 2024 | Rating: 4.1 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%)

Hereditary Angioedema Therapeutic is the treatment for Hereditary Angioedema. Growing cases of hereditary angioedema (HAE) globally is a key market driver.
This report contains market size and forecasts of Hereditary Angioedema Therapeutic in Global, including the following market information:
Global Hereditary Angioedema Therapeutic Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Hereditary Angioedema Therapeutic market was valued at 2149.1 million in 2021 and is projected to reach US$ 3000 million by 2028, at a CAGR of 4.9% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Intravenous Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Hereditary Angioedema Therapeutic include BioCryst Pharma, Ionis Pharma, Pharming Group, CSL Limited, Shire, Attune Pharma, Adverum Biotechnologies and KalVista Pharma, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hereditary Angioedema Therapeutic companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Hereditary Angioedema Therapeutic Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Hereditary Angioedema Therapeutic Market Segment Percentages, by Type, 2021 (%)
Intravenous
Subcutaneous
Oral
Global Hereditary Angioedema Therapeutic Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Hereditary Angioedema Therapeutic Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Others
Global Hereditary Angioedema Therapeutic Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Hereditary Angioedema Therapeutic Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Hereditary Angioedema Therapeutic revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Hereditary Angioedema Therapeutic revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
BioCryst Pharma
Ionis Pharma
Pharming Group
CSL Limited
Shire
Attune Pharma
Adverum Biotechnologies
KalVista Pharma

Frequently Asked Questions
Hereditary Angioedema Therapeutic Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Hereditary Angioedema Therapeutic Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Hereditary Angioedema Therapeutic Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports